Mitchell L. Shiffman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mitchell L. Shiffman has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
Amrita Sethi
Hepatology Section, Virginia Commonwealth University Medical Center, Box 980341, Richmond, VA 23298, USA
1 shared publication
Latest Publications
- 15 July 2005
- Published by Elsevier in Clinics in Liver Disease
- Vol. 9 (3) , 453-471
Approach to the Management of Patients with Chronic Hepatitis C Who Failed to Achieve Sustained Virologic Response
- 15 July 2005
- Published by Elsevier in Clinics in Liver Disease
- Vol. 9 (3) , 453-471
Approach to the Management of Patients with Chronic Hepatitis C Who Failed to Achieve Sustained Virologic Response
- 1 May 2004
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 71 (Suppl_3) , S13
Retreatment of patients who do not respond to initial therapy for chronic hepatitis C.
Despite improvements in the treatment of chronic hepatitis C virus (HCV) infection, nearly half of all patients do not respond to initial therapy. Retreatment of these patients with pegylated interferon and ribavirin has been successful in only a limited percentage of cases. Factors associated with sustained virologic response (SVR) following retreatment include prior treatment with interferon monotherapy, HCV genotype 2 or 3, a low serum HCV RNA level, and the absence of cirrhosis. Fewer than 6% of nonresponders who were previously treated with interferon and ribavirin and who have cirrhosis, genotype 1, and a high viral load achieve SVR following retreatment with pegylated interferon and ribavirin. No therapy has been shown to yield SVR in patients who do not respond to pegylated interferon and ribavirin. Long-term maintenance therapy with pegylated interferon is currently being evaluated in nonresponders with advanced fibrosis and cirrhosis. Its use should be considered investigational at this time.
- 1 May 2004
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 71 (Suppl_3) , S13
Retreatment of patients who do not respond to initial therapy for chronic hepatitis C.
Despite improvements in the treatment of chronic hepatitis C virus (HCV) infection, nearly half of all patients do not respond to initial therapy. Retreatment of these patients with pegylated interferon and ribavirin has been successful in only a limited percentage of cases. Factors associated with sustained virologic response (SVR) following retreatment include prior treatment with interferon monotherapy, HCV genotype 2 or 3, a low serum HCV RNA level, and the absence of cirrhosis. Fewer than 6% of nonresponders who were previously treated with interferon and ribavirin and who have cirrhosis, genotype 1, and a high viral load achieve SVR following retreatment with pegylated interferon and ribavirin. No therapy has been shown to yield SVR in patients who do not respond to pegylated interferon and ribavirin. Long-term maintenance therapy with pegylated interferon is currently being evaluated in nonresponders with advanced fibrosis and cirrhosis. Its use should be considered investigational at this time.